DPP-4 inhibitors like sitagliptin and saxagliptin improve glucose control and reduce inflammation in type 2 diabetes, potentially offering neuroprotective benefits in PD through various molecular pathways. The gene discussed is DPP4; the disease is Parkinson disease.